Catalyst Pharmaceuticals
Coral Gables
About Catalyst Pharmaceuticals
Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse™ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse™ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $273.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:CPRX
- Website: catalystpharma.com
- Phone: +1 305-420-3200
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/catalyst-pharmaceuticals-7532 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.